Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.